Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. Founded in 2018 and headquartered in Buffalo Grove, Illinois, Phathom Pharmaceuticals possesses exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium-competitive acid blocker (PCAB). This groundbreaking medication inhibits acid secretion in the stomach and has shown significant clinical benefits, providing rapid, potent, and sustained acid suppression.
Phathom's flagship product, VOQUEZNA® (vonoprazan), is now FDA-approved and available in the U.S. for treating Erosive Esophagitis (Erosive GERD) and relieving associated heartburn in adults. VOQUEZNA is the first new class of acid suppression medication approved in the U.S. in over 30 years, offering a novel mechanism of action distinct from other treatments. Its efficacy, demonstrated in clinical trials, surpasses that of traditional proton pump inhibitors (PPIs), showcasing strong healing rates and durable results.
In addition to treating GERD, Phathom is developing vonoprazan for use in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® are expected to be commercially available soon, providing comprehensive treatment regimens co-packaged with antibiotics.
Phathom Pharmaceuticals is actively engaged in several key initiatives and collaborations. Recent milestones include the U.S. commercial availability of VOQUEZNA, the completion of Phase 3 trials for Non-Erosive GERD, and the amendment of a term loan facility enhancing financial flexibility. Their innovative approach and dedicated national sales force have driven significant market penetration, with VOQUEZNA now estimated to cover 60 million lives through partnerships with major pharmacy benefit managers.
Phathom is committed to addressing unmet medical needs by offering co-pay assistance programs to ensure accessibility and affordability for patients. They continue to explore new treatment options and expand the indications for vonoprazan through ongoing research and development efforts.
For more information, visit the company’s website at www.phathompharma.com, and follow them on LinkedIn and X (formerly Twitter).
Phathom Pharmaceuticals (Nasdaq: PHAT) announced results from the Phase 2 PHALCON-NERD study on vonoprazan at the ACG 2022 Annual Scientific Meeting. The study involved 207 patients and demonstrated that all three doses of vonoprazan achieved significant heartburn relief: 56% (10 mg), 60.6% (20 mg), and 70% (40 mg) within three hours, compared to 27.3% for placebo (p<0.0001). The trial showed no significant adverse events related to vonoprazan. Phathom is also conducting a Phase 3 trial, with topline data expected in early 2023.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the ACG 2022 Annual Scientific Meeting from October 21-26 in Charlotte, NC. The company will present new data on vonoprazan, a potassium-competitive acid blocker, aimed at treating gastric acid-related disorders. This research addresses conditions such as non-erosive gastroesophageal reflux disease (NERD). Presentations are scheduled for October 24 and 25, with a booth presence at the event. Phathom has a New Drug Application under FDA review for vonoprazan's use in erosive esophagitis.
Phathom Pharmaceuticals (Nasdaq: PHAT) has appointed Dr. James Topper to its Board of Directors. Dr. Topper, Managing Partner at Frazier Life Sciences, returns after previously serving on Phathom's board from 2018 to 2021. His extensive experience includes investments in over 35 biopharma companies and leadership roles in renowned organizations. This appointment comes as Phathom transitions from a clinical-stage to a commercial entity, aiming to launch its products in the first quarter of next year.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference. The management team's on-demand presentation will be available starting September 12, 2022, at 7:00 a.m. ET. The conference runs from September 12-14, and management will also engage in one-on-one meetings. Phathom is focused on novel treatments for gastrointestinal diseases, including its lead product, vonoprazan, which is approved for H. pylori treatment and has an FDA review pending for erosive esophagitis.
Phathom Pharmaceuticals (PHAT) has achieved significant milestones, including the FDA's acceptance of its New Drug Application for vonoprazan in erosive esophagitis (EE), with a PDUFA date set for January 11, 2023. This follows the approval of VOQUEZNA DUAL and TRIPLE PAK for H. pylori infections. Despite detecting trace nitrosamine levels, the company is collaborating with the FDA to ensure compliance and aims for a combined product launch in Q1 2023. The Q2 2022 financial results showed a net loss of $50.9 million, while R&D expenses decreased to $18.8 million.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 p.m. ET. Management will also engage in one-on-one meetings throughout the conference, which runs from June 8-10, 2022. The live webcast and archived recording of the chat will be accessible via the Phathom website for 90 days post-event. Phathom is focused on novel gastrointestinal treatments and has exclusive rights to vonoprazan for H. pylori infection and is awaiting FDA review for erosive esophagitis treatment.
On May 25, 2022, Phathom Pharmaceuticals (Nasdaq: PHAT) announced the FDA's acceptance of its New Drug Application for vonoprazan, targeting erosive esophagitis (EE) and heartburn relief in adults. This application, assigned a standard review, has a PDUFA action date of January 11, 2023. Vonoprazan is a first-in-class potassium-competitive acid blocker, representing the first significant GERD treatment innovation in over 30 years. The application is backed by positive Phase 3 trial results, indicating potential to meet unmet patient needs.
Phathom Pharmaceuticals (Nasdaq: PHAT) presented significant data on vonoprazan at Digestive Disease Week 2022, demonstrating its effectiveness against erosive esophagitis (EE). The Phase 3 PHALCON-EE trial found vonoprazan achieved 92.9% healing by week 8, outperforming lansoprazole (84.6%). At week 24, 80.7% of patients maintained healing with vonoprazan compared to 72.0% with lansoprazole. Additionally, vonoprazan showed superior acid suppression and presented promising data regarding Helicobacter pylori treatment patterns in the U.S., indicating the need for improved management. These findings strengthen vonoprazan's potential in treating EE.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced new investigational data regarding vonoprazan for treating erosive esophagitis (EE) at Digestive Disease Week® (DDW) 2022. The findings reveal real-world evidence highlighting unmet treatment needs for H. pylori infections. Phathom's research received multiple 'posters of distinction' recognition from the American Gastroenterological Association. Notable presentations include Phase 3 results of vonoprazan as monotherapy, demonstrating promising efficacy compared to traditional proton pump inhibitors. The conference takes place from May 21-24 in San Diego, CA.
Phathom Pharmaceuticals (PHAT) announced FDA approval for its VOQUEZNA™ TRIPLE PAK and DUAL PAK for treating H. pylori infections in adults. This marks a significant regulatory milestone for the company. Additionally, it secured a revenue interest financing agreement of up to $260 million, providing a strong capital foundation without diluting shareholder equity. Financial results for Q1 2022 reflect a net loss of $40.7 million, an increase from $34.8 million in Q1 2021, indicating ongoing investment in commercial launch and R&D while reducing expenses in certain areas.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
What does Phathom Pharmaceuticals focus on?
What is vonoprazan?
What conditions does VOQUEZNA treat?
What makes VOQUEZNA unique?
Are there other products in development at Phathom?
Where is Phathom Pharmaceuticals headquartered?
When was Phathom Pharmaceuticals incorporated?
What recent financial milestone did Phathom achieve?
How can patients afford VOQUEZNA?
Where can I find more information about Phathom Pharmaceuticals?
